W. P. Carey (WPC)
NYSEReal EstateReit - DiversifiedSnapshot 2026-10-29
$64.89+2.87%
Close 2026-10-29 · 1-day change
NYSEReal EstateReit - DiversifiedSnapshot 2026-10-29
Research Workspace
Put WPC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Real Estate is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskHealthy across the board
WPC’s case rests on steady property earnings, backed by cash, with raised AFFO guidance supporting growth. Revenue growth eased from 10.9% in Q1 to 7.0% in Q2, then reached 8.6% in Q3. The latest result beat by 6%, and management raised 2026 AFFO guidance. WPC trades at 12× P/FFO versus a 12× peer median. The price reflects less growth than our forecast, despite its below-sector earnings yield. A 37% next-quarter miss probability and a weak real estate sector threaten the case. Peer multiples imply a price about 5% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-29. WPC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering WPC (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for WPC in the last 4 months.
Continue this research
Compare WPC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| WPC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified REITs — fair value, gap to price, and forward P/E.
Compare the value case
Put WPC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Raise 2026 AFFO guidance
2026 AFFO guidance and planned investment volume directly support growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $64.89
The last 12 months of price, then the range of analyst 12-month targets from today’s $64.89.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Raise 2026 AFFO guidance
Raised AFFO guidance supports growth objectives.
Threatens: Increase cash from operating activities
Bankruptcy impact may reduce operating cash flow.
Advances: Maintain disciplined capital allocation with debt issuances and repayments
Issuing notes supports disciplined capital allocation.
Advances: Maintain disciplined capital allocation with debt issuances and repayments
New notes issuance supports disciplined capital allocation.
Tenant bankruptcy may impact cash flow and AFFO guidance.
Advances: Increase dividend per share
Dividend increase aligns with capital allocation goals.
Advances: Deploy capital accretively with strong investment pipeline
Record investments indicate strong investment pipeline.
